Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05363631 · ClinicalTrials.gov registry record · Phase 1
Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab
A Phase 1 study of Clear Cell Renal Cell Carcinoma and Clear Cell Renal Cell Carcinoma Metastatic, sponsored by Mohammed Milhem.
- Active
- Registry status
- Phase 1
- Development phase
- 55
- Enrollment target
- 1
- Study location
NCT05363631: Active Phase 1 study of Clear Cell Renal Cell Carcinoma and Clear Cell Renal Cell Carcinoma Metastatic, sponsored by Mohammed Milhem.
NCT05363631 is a Phase 1 study of Clear Cell Renal Cell Carcinoma and Clear Cell Renal Cell Carcinoma Metastatic that is active but no longer recruiting, run by Mohammed Milhem. The registered enrollment target is 55 participants, below the 202-participant average among 45 other Clear Cell Renal Cell Carcinoma trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05363631, a Phase 1 study of Clear Cell Renal Cell Carcinoma and Clear Cell Renal Cell Carcinoma Metastatic, is active but no longer recruiting, sponsored by Mohammed Milhem.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 55 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to test the safety and effectiveness of Seleno-L Methionine (SLM) when combined with the standard dose and schedule of Axitinib and Pembrolizumab in patients who have locally advanced or metastatic clear cell renal cell carcinoma (ccRCC).
Primary Outcome
To examine the toxicity related to the therapy by measuring the number of treatment related adverse events in patients
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Axitinib
- DRUG Selenomethionine (SLM)
Study Locations (1)
Iowa
- University of Iowa Hospitals & Clinics - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2022-09-19 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
What the registry record for NCT05363631 still lists
NCT05363631 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 202-participant average among 45 other Clear Cell Renal Cell Carcinoma trials with a reported enrollment target (73% lower).
The record links to 2 conditions, with Clear Cell Renal Cell Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT05363631 reports a single indexed study location in Iowa.
Frequently Asked Questions
What is clinical trial NCT05363631 about?
NCT05363631 is a clinical study titled "Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab". The purpose of this research study is to test the safety and effectiveness of Seleno-L Methionine (SLM) when combined with the standard dose and schedule of Axitinib and Pembrolizumab in patients who have locally advanced or metastatic clear cell renal cell carcinoma (ccRCC).
What is the current status of trial NCT05363631?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2022-09-19. Estimated completion is 2026-12-31.
What conditions does trial NCT05363631 study?
This clinical trial studies the following conditions: Clear Cell Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma Metastatic.
What interventions are being tested in trial NCT05363631?
The interventions under investigation include: Pembrolizumab (DRUG), Axitinib (DRUG), Selenomethionine (SLM) (DRUG).
Who is sponsoring clinical trial NCT05363631?
This trial is sponsored by Mohammed Milhem, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05363631 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Clear Cell Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05363631's enrollment target sits among peer trials
55 32nd of 45 higher than 14 of 45 other Clear Cell Renal Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Clear Cell Renal Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Beta-only IL-2 ImmunoTherapY Study
RECRUITING · Phase 1
-
A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
RECRUITING · Phase 1
-
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
RECRUITING · Phase 1
-
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
RECRUITING · Phase 1
-
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
RECRUITING · Phase 1
-
[18F]PT2385 PET/CT in Patients With Renal Cell Carcinoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI